Literature DB >> 3126296

Inhibition of porcine pepsin by two substrate analogues containing statine. The effect of histidine at the P2 subsite on the inhibition of aspartic proteinases.

J Maibaum1, D H Rich.   

Abstract

Two new inhibitors, 4 and 5, of the aspartic proteinase porcine pepsin were synthesized. These compounds, which span the P4-P'3 binding subsites of the enzyme, were derived by replacing the Nph-Phe dipeptidyl unit of a good pepsin substrate, H2N-Phe-Gly-His-Nph-Phe-Ala-Phe-OMe (3), with statine [(3S,4S)-4-amino-3-hydroxy-6-methylheptanoic acid, Sta]. Hexapeptide 5, H2N-Phe-Gly-Val-(S,S)-Sta-Ala-Phe-OMe, is an extremely potent inhibitor of pepsin with a Ki value less than 1 nM. This result is consistent with the proposal that statine functions as a bioisosteric replacement for a substrate dipeptidyl unit. Compound 4, which contains His at P2, is 2 orders of magnitude less active than the valine analogue 5 (Ki = 150 nM). The factor for the decrease in binding to pepsin effected by replacement of Val by His at P2 parallels the ratio of protonated vs unprotonated imidazole group in peptide 4 at pH 4, according to the Henderson-Hasselbach equation. This result suggests that a positively charged side chain at P2 is undesirable for maximum pepsin inhibition. Kinetic constants for several known inhibitors of pepsin and renin are presented that demonstrate that the effect of His incorporation at P2 on pepsin inhibition depends upon the peptide sequence and that the effect is considerably different for renin inhibitors. We further suggest that the high selectivity of potent renin inhibitors known to be only weak pepsin and cathepsin D inhibitors is due in part to the extent of histidine protonation at P2 arising from pH differences in the inhibition kinetics assay of renin (neutral conditions) compared to other aspartic proteinases (acid pH 2-4).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3126296     DOI: 10.1021/jm00398a022

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.

Authors:  Yu-Chung E Chang; XiaXia Yu; Ying Zhang; Yunfeng Tie; Yuan-Fang Wang; Sofiya Yashchuk; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2012-03-22       Impact factor: 7.446

2.  Structural and biochemical characterization of the inhibitor complexes of xenotropic murine leukemia virus-related virus protease.

Authors:  Mi Li; Alla Gustchina; Krisztina Matúz; Jozsef Tözsér; Sirilak Namwong; Nathan E Goldfarb; Ben M Dunn; Alexander Wlodawer
Journal:  FEBS J       Date:  2011-10-10       Impact factor: 5.542

3.  The selectivity of statine-based inhibitors against various human aspartic proteinases.

Authors:  R A Jupp; B M Dunn; J W Jacobs; G Vlasuk; K E Arcuri; D F Veber; D S Perlow; L S Payne; J Boger; S de Laszlo
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

4.  Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.

Authors:  Fengling Liu; Andrey Y Kovalevsky; Yunfeng Tie; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2008-07-01       Impact factor: 5.469

5.  Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir.

Authors:  Andrey Y Kovalevsky; Arun K Ghosh; Irene T Weber
Journal:  J Med Chem       Date:  2008-09-20       Impact factor: 7.446

6.  Substrate and inhibitor studies with human gastric aspartic proteinases.

Authors:  A Baxter; C J Campbell; C J Grinham; R M Keane; B C Lawton; J E Pendlebury
Journal:  Biochem J       Date:  1990-05-01       Impact factor: 3.857

7.  Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.

Authors:  Fengling Liu; Peter I Boross; Yuan-Fang Wang; Jozsef Tozser; John M Louis; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2005-10-21       Impact factor: 5.469

8.  Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114.

Authors:  Andrey Y Kovalevsky; Fengling Liu; Sofiya Leshchenko; Arun K Ghosh; John M Louis; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2006-08-04       Impact factor: 5.469

9.  Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors.

Authors:  Yunfeng Tie; Yuan-Fang Wang; Peter I Boross; Ting-Yi Chiu; Arun K Ghosh; Jozsef Tozser; John M Louis; Robert W Harrison; Irene T Weber
Journal:  Protein Sci       Date:  2012-01-24       Impact factor: 6.725

10.  Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.

Authors:  Andrey Yu Kovalevsky; Yunfeng Tie; Fengling Liu; Peter I Boross; Yuan-Fang Wang; Sofiya Leshchenko; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2006-02-23       Impact factor: 7.446

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.